Chippenham-based pharmaceutical product developer Vectura announced the appointment of a new CFO this week, as it posted six-monthly results with revenues up 14 percent.
Vectura, which specialises in the development of products for the treatment of airways diseases, recorded revenues of £19.4 million in the six months up to September 30, according to figures published this week.
It also announced that Andrew Oakley will succeed Paul Oliver as CFO on January 1. He will also take up the roles of executive director and company secretary.
Oakley has spent almost 11 years at Swiss bio-pharmaceutical company Actelion as CFO. After leaving Actelion in 2013, he served as CFO at privately held Swiss biotech Novimmune.
Dr Chris Blackwell, chief executive of Vectura, said: “We are delighted to welcome Andrew to Vectura at this exciting period in the Company's growth plans.
“Andrew is an established and well-regarded CFO who has gained considerable relevant experience within a leading European pharmaceutical company.
“His strong financial control, market knowledge and transaction experience will be a considerable asset for Vectura.
"The Board would like to thank Paul for his considerable contribution to the Company over the past eight years. Since joining Vectura, Paul has contributed to the growth of Vectura and to the successful acquisitions and subsequent integrations of Innovata plc and Activaero GmbH.
“We wish him continued success in his future career."